Foreword

Human & Experimental Toxicology

Volumn 15, Issue 9, 1996, Pages 752-785

[No Author Info available]

Author keywords

Caelyx ; doxorubicin; drug regulation; EC Expert Report; liposome; non clinical data

Indexed keywords

EID: 84992784779     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/096032719601500906     Document Type: Article

References (68)

1. Lasic D & Martin F, eds. Stealth Liposomes. Boca Raton: CRC Press, 1995.
2. Benjamin RS, Wiernik PH & Bachur NR Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent singe high-dosage schedule. Cancer 1974; 33: 19-27.
3. Minow RA, Benjamin RS, Lee ET & Gottlieb JA Adriamycin cardiomyopathy: Risk factors. Cancer 1977; 39: 1397-402.
4. Von Hoff DD, Layard MW, Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979; 91: 710-7.
5. Maral RJ & Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treatment Reports 1981; 65 (Supplement 4): 9-18.
6. Wright JC Cancer chemotherapy: Past, present and future - Part I. Journal of the National Medical Association 1984; 76: 773-84.
7. Legha SS, Hortobagyi GN & Benjamin RS (JJ Lokich, ed.) Anthracyclines. Cancer Chemotherapy by Infusion. Chicago: Precept Press, 1987 pp. 130-44.
8. Pigram WJ, Fuller W. & Hamilton LD Stereochemistry of intercalation. Interaction of daunomycin with DNA. Nature 1972; 235: 17-9.
9. Pindur U., Haber M. & Sattler K. Antitumor active drugs as intercalators of deoxyribonucleic acid. Journal of Chemical Education 1993; 4: 263-72.
10. Zhang H., Gao Y., van de Marel GA & Wang AH-J. Simultaneous incorporations of two anticancer drugs into DNA. Journal of Biological Chemistry 1993; 268: 10095-101.
11. Hickman J., Chahwala SB & Thompson EG Interaction of the antibiotic Adriamycin with the plasma membrane. Advances in Enzyme Regulation 1985; 24: 263 -74.
12. Santone KS, Oakes SG, Taylor SR & Powis G. Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. Cancer Research 1986; 46: 2659-64.
13. Pommier Y., Schwartz RE, Zwelling LA & Kohn KW Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 1985; 24: 6406-10.
14. Tewey KM, Rowe TC, Yang L., Halligan BD & Liu LF Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
15. Bachur NR, Gee MV & Gordon SL Enzymatic activation of actinomycin D ACTD to free radical state. Proceedings of the American Association of Cancer Research 1978; 19: 75-9.
16. Berlin V. & Haseltine WA Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. Journal of Biological Chemistry 1981; 256: 4747-56.
17. Powis GP Metabolism and reactions of quinoid anticancer agents. Pharmacological Therapeutics 1987; 35: 57-162.
18. Zwelling LA, Kerrigan D. & Michael S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells. Comparison with Adriamycin and 4'-9-acridinylamino methanesulfono-m-anisidine. Cancer Research 1982; 42: 2687-91.
19. Needham D., McIntosh TJ & Lasic DD Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochimica Biophysica Acta 1992; 1108: 40-8.
20. Dvorak HF, Nagy JA, Dvorak JT & Dvorak AM Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. American Journal of Pathology 1988; 133: 95-109.
21. Wu NZ & Dewhirst MW Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy. Microvascular Research 1993; 46: 231 - 53.
22. Speth Paj, van Hoesel Qgcm & Haanen C. Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics 1988; 15: 15-31.
23. Greene RF, Collins JM, Jenkins JF, Speyer JL & Myers CE Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Research 1983; 43: 43: 3417-21.
24. Speth Paj, Linssen Pcm, Holdrinet Rsg & Haanen C. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clinical Pharmacology and Therapeutics 1987; 41: 661-5.
25. Speth Paj, Linssen Pcm, Boezeman Jbm, et al. Cellular and plasma Adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemotherapy and Pharmacology 1987; 20: 305-10.
26. Yesair DW, Schwartzbach E., Shuck D., Denine EP & Asbell AS Comparative pharmacokinetics of Daunomycin and Adriamycin in several animal species. Cancer Research 1972; 32: 1177-83.
27. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE & Young RC Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Research 1979; 39: 3209-14.
28. Oosterbaan MJ, Dirks RJ, Vree TB & van der Kleijn E. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. Pharmaceutical Research 1984; 1: 33 -8.
29. Cusack BJ, Young SP, Loseke VL, Hurty MR, Beals L. & Olson RD Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemotherapy and Pharmacology 1992; 30: 145-8.
30. Riggs CE, Benjamin RS, Serpick AA & Bachur NR Biliary disposition of Adriamycin. Clinical Pharmacology and Therapeutics 1977; 22: 234-41.
31. Benjamin RS, Riggs CE & Bachur NR Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 1977; 37: 1416-20.
32. Takanashi S. & Bachur NR Adriamycin metabolism in man, evidence for urinary metabolites. Drug Metabolism and Disposition 1976; 4: 79-87.
33. Gabizon A., Barenholz Y. & Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharmaceutical Research 1993; 10: 703-8.
34. Gabizon A., Catane R., Uziely B., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research 1994; 54: 987-92.
35. Legha SS, Benjamin RS, Mackay B., et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982; 49: 1762-6.
36. Lokich JJ & Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 1984; 101: 798-800.
37. Vogelzang NJ & Ratain MJ Cancer chemotherapy and skin changes. Annals of Internal Medicine 1985; 103: 303-4.
38. Riggs CE, Jr. & Bachur NR (MM Ames, G Powis, & JS Kovach, eds.) Clinical pharmacokinetics of anthracycline antibiotics. Pharmacokinetics of Anticancer Agents in Humans. Amsterdam and New York: Elsevier, 1983 pp. 229-78.
39. Johnson AH, Darpatkin HH & Newman J. Clinical investigation of intermediate-and high-purity antihaemophilic factor (factor VIII) concentrates. British Journal of Hematology 1971; 21: 21-41.
40. Shaffer CB & Critchfield FH The absorption and excretion of the solid polyethylene glycols. Journal of the American Pharmacological Association 1947; 36: 152-7.
41. Carpenter CP, Woodside MD, Kinkead ER, King JM & Sullivan LJ Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicology and Applied Pharmacology 1971; 18: 35-40.
42. Jaenke RS An anthracycline antibiotic-induced cardiomyopathy in rabbits. Laboratory Investigation 1974; 30: 292 - 304.
43. Iatropoulos MJ Anthracycline cardiomyopathy: Predictive value of animal models. Cancer Treatment Symposium 1984; 3: 3-17.
44. Thompson D., Molello JA, Strebing RJ et al. Teratogenicity of Adriamycin and Daunomycin in the rat and rabbit. Teratology 1978; 17: 151-8.
45. Physicians' Desk Reference 45th Edition. Oradell NJ: Medical Economics Data, 1991, pp. 559-62.
46. Ansell GB, Dawson Rmc & Hawthorne NJ Form and Function of Phospholipids. Amsterdam: Elsevier, 1973.
47. Smyth HF, Carpenter CP & Weil CS The chronic oral toxicity of the polyethylene glycols. Journal of the American Pharmacological Association 1950; 44: 27-30.
48. Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemotherapy Reports 1966; 50: 219-44.
49. Wolf A., Saito T., Dudek R. & Bing RJ The effect of lysophosphatidylcholine on coronary and renal circulation in the rabbit. Lipids 1991; 26: 223-6.
50. Rudolph R., Stein RS & Pattillo RA Skin ulcers due to Adriamycin. Cancer 1976; 38: 1087-94.
51. Samuels BL, Vogelzang NJ, Ruane M. & Simon MA Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treatment Reports 1987; 71: 971-2.
52. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M. & Sinkule JA Pharmacokinetics and pharmacodynamics of long-term continuous-infusion of doxorubicin. Clinical Pharmacology and Therapeutics 1989; 45: 340-7.
53. Dantchev D., Slioussartchouk V., Paintrand M., Hayat M., Bourut C. & Mathe G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of Golden hamsters with Adriamycin, Detorubicin, AD-32 and Aclacinomycin. Cancer Treatment Reports 1979; 63: 875-88.
54. Lu CC & Meistrich ML Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Research 1979; 39: 3575-82.
55. Chapman RM, Sutcliffe SB, Rees LH, Edwards Crw & Malpas JS Cyclical combination chemotherapy and gonadal function. Lancet 1979; 1: 285-9.
56. Whitehead E., Shalet SM, Blackledge G., Todd I., Crowhter D. & Beardwell CG The effects of Hodgkin's disease and combination chemotherapy on gonadal infusion in the adult male. Cancer 1982; 49: 418-22.
57. Fuse H., Iwasaki M. & Katayama T. Endocrine/ histological parameters of spermatogenic damage in doxorubicin-treated rats. Advances in Controlled Delivery Systems 1992; 8: 33-40.
58. Bertazzoli C., Chieli T., & Solcia E. Different incidence of breast carcinomas or fibroadenomas in Daunomycin or Adriamycin treated rats. Experientia 1971; 27: 1209-10.
59. Solcia E., Ballerini L., Bellini O., Sala L., & Bertazzoli C. Mammary tumors induced in rats by Adriamycin and Daunomycin. Cancer Research 1978; 38: 1444-6.
60. Gabizon A., Amselem S., Goren D., et al. Preclinical and clinical experience with a doxorubicin-liposome preparation. Journal of Liposome Research 1990; 1: 491-502.
61. Gabizon A., Chisin R., Amselem S. et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. British Journal of Cancer 1991; 64: 1125 -32.
62. Wu NZ, Da D., Rudoll TL, Needham D., Whorton AR & Dewhirst MW Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Research 1993; 53: 3765-70.
63. Huang SK, Lee K-D., Hong D., Friend DS & Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Research 1992; 52: 5135-43.
64. Huang SK, Martin FJ, Jay G., Vogel J., Papahadjopoulos D. & Friend DS Extravasation and transcytosis of liposomes in Kaposi's Sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. American Journal of Pathology 1993; 143: 10-14.
65. Woodle MC & Lasic DD Sterically stabilized liposome. Biochimica Biophysica Acta 1992; 1113: 171-99.
66. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence cardiotoxicity. Cancer Treatment Reports 1980; 64: 47-51.
67. Lokich JJ, Bothe A., Zipoli T. et al. Constant infusion schedule for Adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. Journal of Clinical Oncology 1983; 1: 24-8.
68. Tietz NW Clinical Chemistry. Philadelphia: WB Saunders Company, 1986.